Health Care Knowledge

Introduction: In 2001, Imatinib was approved for medical use in the United States. It is used for the treatment of cancer. Specifically, it is introduced for chronic myelogenous leukemia and acute lymphocytic leukemia that are Ph+, certain gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), myelodysplastic syndrome and systemic mastocytosis.  What is Imatinib? Imatinib 400 mg is an oral chemotherapy medication . It acts by stopping the Bcr-Abl tyrosine-kinase. This can resist the growth or outcomes in programmed cell death of certain sorts of cancerous cells. Imatinib is introduced in order to be used for the treatment of patients with chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. In the year of 2006 the FDA extended the approved use to include DFSP (Dermatofibrosarcoma protuberans), (Myelodysplastic/myeloproliferative diseases (MDS/MPD), Aggressive systemic mas

Introduction: Exemestane is a drug used for the treatment of breast cancer. It falls under the class of antiestrogens known as aromatase inhibitors. Certain breast cancers basically need estrogen to grow. Those cancers have estrogen receptors (ERs), and are named ER+. They may also be named estrogen-responsive, hormonally-responsive, or HR+. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors inhibit the synthesis of estrogen. This reduces the estrogen level, and resists the growth of cancers. What is Exemestane? Exemestane is used for the adjuvant treatment of postmenopausal women with ER +Ve early breast cancer who have alreadt taken 24 to 36 months of tamoxifen and are switched to it for finishing of a total of 5 consecutive years of adjuvant hormonal therapy.  Exemestane 25 mg tablet is also introduced to treat advanced breast cancer in postmenopausal women whose disease has progressed after the tamoxifen therapy. For premenopausal women with HR+ breast cancer,